Rare Disease Report

VBP15 To Treat Duchenne Muscular Dystrophy - Clinical Trial Update

APRIL 22, 2015

In this interview, Eric Hoffman, PhD, president and chief executive officer of ReveraGen Biopharma, provides an update on the phase 1 and 2 studies either underway or planned for the use of VBP15 to treat patients with Duchenne muscular dystrophy.

For more information, click here.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.